{"entity":{"id":"nct00272649","kind":"trial","name":"Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer","aka":[],"tldr":"A phase 1/2 trial of Rocapuldencel-T run by Argos Therapeutics, completed.","summary":"Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer is a phase 1/2 interventional study registered as NCT00272649 by Argos Therapeutics, with 22 participants enrolled, started 2006-01. Conditions recorded: Renal Cell Carcinoma. Interventions recorded: AGS-003.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT00272649","url":"https://clinicaltrials.gov/study/NCT00272649"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["rocapuldencel-t"],"companies":["argos-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00272649","phase":"1/2","setting":"A Phase I/II Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma","sponsor":"Argos Therapeutics","enrolled":22,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00272649/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"rocapuldencel-t","kind":"drug","name":"Rocapuldencel-T","route":"/drugs/rocapuldencel-t/"}],"company":[{"id":"argos-therapeutics","kind":"company","name":"Argos Therapeutics","route":"/companies/argos-therapeutics/"}]}}